You are here

Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42NS098918-02A1
Agency Tracking Number: R42NS098918
Amount: $1,924,133.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NINDS
Solicitation Number: PA19-270
Timeline
Solicitation Year: 2019
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-01-01
Award End Date (Contract End Date): 2023-08-31
Small Business Information
17062 MURPHY AVE
Irvine, CA 92614-5914
United States
DUNS: 927045336
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 KEITH BOOHER
 (949) 679-1190
 kbooher@zymoresearch.com
Business Contact
 MARC VANEDEN
Phone: (949) 679-1190
Email: mvaneden@zymoresearch.com
Research Institution
 UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
 
7000 FANNIN STREET, UCT 1000
HOUSTON, TX 77030-5400
United States

 Nonprofit College or University
Abstract

PROJECT SUMMARY/ABSTRACT
Stroke injury occurs over a long duration through pathologic changes leading to long-term neurologic
dysfunction. There is an urgent need of therapeutic strategies that can provide safe and efficacious therapeutic
effects to the hypoperfused brain with long-lasting endogenous neuroprotection for prevention of long-term
neurologic dysfunction. Sufficient evidence has pointed out that xenon (Xe), a bioactive gas, has profound
neuroprotective effects with advantages of rapid diffusion across the blood-brain barrier (BBB) with minimal side
effects. Researchers at The University of Texas Health Science Center at Houston (UTSCH-H) have been able
to incorporate Xe into liposomes and demonstrated that Xe-liposomal treatment post-stroke resulted in activation
of endogenous brain protection following ischemic stroke. Corroborated mechanisms of Xe cytoprotection
include the activation of endogenous cytoprotective molecules. In a NIH Phase I STTR, UTHSC-H collaborated
with Zymo Research Corporation (Zymo), an experienced epigenetics company. We have shown proof of
concept that intermittent Xenon(Xe)-liposomal treatment after stroke extends endogenous neuroprotection and
induces epigenetic changes. Such sustained endogenous neuroprotection can be distinguished by a panel of
differentially methylated biomarkers indicative of activation of specific signal transduction pathways. As brain
pathological changes/progression post stroke last for months, to be clinically useful, to extend the window for
neuroprotection duration. We hypothesize that endogenous neuroprotection seen via epigenetic markers can be
enhanced and consolidated and into the chronic recovery phase, meanwhile, translate to clinical relevant model.
We do this with a three-phase Xenon administration strategy. Two Xe formulations, Xe- liposomes and oral Xe
formulation, will be used to extend the treatment window. We will establish maximal therapeutic efficacy and
then translate into aged rat to increase rigor. The epigenetic biomarker panel identified in the Phase I STTR will
be used to assess and validate Xe long term neuroprotective effects via the 3-phased administration regime in
our Phase 2 STTR. Our goal is to optimize, validate, and translate the Xe liposomal formulation from phase I
and evaluate a new complementary Xenon cyclodextrin (Xe-CD) formulation for oral administration for the
chronic stroke recovery phase, whilst commercializing both Xe intravenous and oral formulations. We will
continue epigenetic biomarker development as a diagnostic tool for evaluating stroke progression and treatment
effects.
Our aims are: 1) to develop final formulations of Xe-liposomes and Xe-enriched solution, and to evaluate
parameters for product reproducibility and analysis pharmacokinetics of both formulations; 2) to maintain
neuroprotection over a longer duration by adding an oral Xe-CD formulation following the IV acute Xe-liposomal
agent administration (Acute to Chronic Recovery Strokes) in both adult and aged animals; and 3) to finalize, and
scale the Xe-Liposomal and Xe-CD-Oral formulations for an IND application.
Our long-term goal is to bring this strategy and these two formulations into clinical trials to stabilize and treat
stroke from the acute to the long term recovery phase.PROJECT NARRATIVE
Stroke injury occurs over a long duration through pathologic changes leading to long-term neurologic
dysfunction. Neuroprotection for a long period post stroke could prevent or slow neurovascular deterioration. We
aim to establish and translate two therapeutic agents (Xenon liposomes and Xe oral formulations) along with a
novel delivery strategy to stimulate and consolidate long-term endogenous cytoprotection and tolerance to
provide new opportunities for more complete stroke treatment. Identification of reliable biomarkers to guide
determination of best frequency and duration of xenon-containing formulations and a translatable therapeutic
administration protocol that allows consistent, long-lasting protection post stroke.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government